Literature DB >> 29870795

Importance of control groups when delineating antibiotic use as a risk factor for carbapenem resistance, extreme-drug resistance, and pan-drug resistance in Acinetobacter baumannii and Pseudomonas aeruginosa: A systematic review and meta-analysis.

Cheryl Li Ling Lim1, Alvin Qijia Chua2, Jocelyn Qi Min Teo2, Yiying Cai2, Winnie Lee2, Andrea Lay-Hoon Kwa3.   

Abstract

BACKGROUND: Carbapenem-resistant (CR), extremely drug-resistant (XDR), and pan-drug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa pose a huge clinical threat. This study reviews the impact of control groups on the association of antecedent antibiotic use and the acquisition of CR/XDR/PDR A. baumannii and P. aeruginosa.
METHODS: Studies investigating the role of antibiotics as a risk factor for CR/XDR/PDR A. baumannii and P. aeruginosa acquisition in adult hospitalized patients from 1950 to 2016 were identified in the databases. These were divided into two groups: antibiotic-resistant versus antibiotic-sensitive pathogens (group I); antibiotic-resistant versus no infection (group II). A random-effects model was performed.
RESULTS: Eighty-five studies (46 A. baumannii, 38 P. aeruginosa, and one of both) involving 22 396 patients were included. CR was investigated in 60 studies, XDR in 20 studies, and PDR in two studies. Prior antibiotic exposure was associated with significant acquisition of CR/XDR/PDR A. baumannii and P. aeruginosa in both groups I and II (p<0.05). Antibiotic classes implicated in both groups included aminoglycosides, carbapenems, glycopeptides, and penicillins. Cephalosporin use was not associated with resistance in either group. Fluoroquinolone exposure was only associated with resistance in group I but not group II.
CONCLUSIONS: Control groups play an important role in determining the magnitudes of risk estimates for risk factor studies, hence careful selection is necessary. Antibiotic exposure increases the acquisition of highly resistant A. baumannii and P. aeruginosa, thus appropriate antibiotic use is imperative.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Antibiotic; Carbapenem resistance; Controls; Extreme drug resistance; Pan-drug resistance; Pseudomonas aeruginosa; Risk factor

Mesh:

Substances:

Year:  2018        PMID: 29870795     DOI: 10.1016/j.ijid.2018.05.017

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

1.  Successful Incidences of Controlling Multidrug-Resistant, Extensively Drug-Resistant, and Nosocomial Infection Acinetobacter baumannii Using Antibiotic Stewardship, Infection Control Programs, and Environmental Cleaning at a Chinese University Hospital.

Authors:  Lei Liu; Bin Liu; Wei Li
Journal:  Infect Drug Resist       Date:  2020-07-27       Impact factor: 4.003

2.  Microbial Landscape and Antibiotic Susceptibility Dynamics of Skin and Soft Tissue Infections in Kazakhstan 2018-2020.

Authors:  Sholpan S Kaliyeva; Alyona V Lavrinenko; Yerbol Tishkambayev; Gulzira Zhussupova; Aissulu Issabekova; Dinara Begesheva; Natalya Simokhina
Journal:  Antibiotics (Basel)       Date:  2022-05-13

3.  Antibiotic Resistance in Pseudomonas spp. Through the Urban Water Cycle.

Authors:  Anca Butiuc-Keul; Rahela Carpa; Dorina Podar; Edina Szekeres; Vasile Muntean; Dumitrana Iordache; Anca Farkas
Journal:  Curr Microbiol       Date:  2021-02-24       Impact factor: 2.188

4.  Decreasing incidence of Acinetobacter baumannii pneumonia and trends in antibiotic consumption: A single-center retrospective observational study.

Authors:  Andrew T Peters; Chiagozie I Pickens; Michael J Postelnick; Teresa R Zembower; Chao Qi; Richard G Wunderink
Journal:  Infect Control Hosp Epidemiol       Date:  2021-08-13       Impact factor: 6.520

5.  Inhaled amikacin versus placebo to prevent ventilator-associated pneumonia: the AMIKINHAL double-blind multicentre randomised controlled trial protocol.

Authors:  Elsa Tavernier; Francois Barbier; Ferhat Meziani; Jean-Pierre Quenot; Jean-Etienne Herbrecht; Mickael Landais; Damien Roux; Philippe Seguin; David Schnell; Anne Veinstein; Benoît Veber; Sigismond Lasocki; Qin Lu; Gaetan Beduneau; Martine Ferrandiere; Claire Dahyot-Fizelier; Gaetan Plantefeve; Mai-Anh Nay; Hamid Merdji; Pascal Andreu; Laurent Vecellio; Grégoire Muller; Maria Cabrera; Deborah Le Pennec; Renaud Respaud; Philippe Lanotte; Nicolas Gregoire; Marie Leclerc; Julie Helms; Thierry Boulain; Jean-Claude Lacherade; Stephan Ehrmann
Journal:  BMJ Open       Date:  2021-09-14       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.